Blog

Razan Mohty: Metanalysis on role of alloHCT in VEXAS syndrome

Photo from Razan Mohty/X

Jul 31, 2024, 11:15

Razan Mohty: Metanalysis on role of alloHCT in VEXAS syndrome

Razan Mohty, Assistant Professor at UAB Medicine, O’Neal Comprehensive Cancer Center, made the following announcement on Twitter:

“Check our metanalysis on role of alloHCT in VEXAS syndrome published in Bone Marrow Transplantation Journal
alloHCT is an effective treatment for patients with VEXAS syndrome.

‘Assessing the efﬁcacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis’

Authors: Razan Mohty, Tea Reljic, Nayef Abdel-Razeq, Omer Jamy, Talha Badar, Ambuj Kumar, Mahmoud Aljurf & Mohamed A. Kharfan-Dabaja.”

Source: Razan Mohty/X

Ambuj Kumar Bone Marrow Transplantation cancer Mahmoud Aljurf & Mohamed A. Kharfan-Dabaja Nayef Abdel-Razeq Omer Jamy OncoDaily Oncology Razan Mohty Talha Badar Tea Reljic VEXAS syndrome

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage